SE486-11

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Arndt, Greg M: 1 article (01/2021)
2.	Carter, Daniel R: 1 article (01/2021)
3.	Cheung, Belamy B: 1 article (01/2021)
4.	Ciampa, Olivia C: 1 article (01/2021)
5.	Diakiw, Sonya M: 1 article (01/2021)
6.	Gadde, Satyanarayana: 1 article (01/2021)
7.	Gong, Andrew: 1 article (01/2021)
8.	Haber, Michelle: 1 article (01/2021)
9.	Holien, Jessica K: 1 article (01/2021)
10.	Kim, Patrick Y: 1 article (01/2021)

1.	Carcinogenesis 01/01/2021 - "Treatment with SAHA and SE486-11 increased MYCN ubiquitination and degradation, and markedly inhibited tumorigenesis in neuroblastoma xenografts, and, MYCN transgenic zebrafish and mice. "
2.	Neuroblastoma 01/01/2021 - "Treatment with SAHA and SE486-11 increased MYCN ubiquitination and degradation, and markedly inhibited tumorigenesis in neuroblastoma xenografts, and, MYCN transgenic zebrafish and mice. " 01/01/2021 - "Thus, USP5 acts as an oncogenic cofactor with MYCN in neuroblastoma and the novel combination of HDAC inhibitor with SE486-11 represents a novel therapeutic approach for the treatment of MYCN-driven neuroblastoma."

1.	Histone Deacetylase Inhibitors